Last reviewed · How we verify
No antiplatelet therapy
At a glance
| Generic name | No antiplatelet therapy |
|---|---|
| Sponsor | Jung-min Ahn |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation (NA)
- Tanhuo Decoction for Acute Coronary Syndrome With Cerebral Atherosclerosis in Elderly Patients (NA)
- REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts (PHASE3)
- EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF) (PHASE4)
- Adjuvant Clopidogrel in Staphylococcus Aureus Bacteremia (PHASE2)
- DAPT Strategy in HBR Patients Undergoing Complex PCI Following ACS: Second-Phase Beta Testing of a Patients Decision Aid (NA)
- Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38) (NA)
- Antiplatelet Use in Dementia Subtypes
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- No antiplatelet therapy CI brief — competitive landscape report
- No antiplatelet therapy updates RSS · CI watch RSS
- Jung-min Ahn portfolio CI